Studies have suggested that patients with NSCLC lacking driver oncogenes may demonstrate a more favorable response to immune checkpoint inhibitor therapy than patients with oncogene-addicted NSCLC, particularly those with EGFR/ALK variations (Lisberg et al., 2018; Addeo et al., 2021). This evidence concerns the gene EGFR and non-small cell lung carcinoma.